Immunohistochemical localization of factor VIII-related antigen was studied in human tissues obtained at autopsy or renal biopsy, umbilical cord vessels, smears of washed blood cells and cultured human endothelial cells. Factor VIII-related antigen was demonstrated in the vascular intima throughout the body and cells lining the sinusoids of the lymph node, spleen and liver by an indirect immuno...

Patients with coagulation factor(s) deficiency who use coagulation therapy are susceptible to forming inhibitors against coagulation factor(s). In this survey we detected factor V and VIII inhibitor in ten patients with combined deficiency of factors V and VIII from north east of Iran (Khorassan province). It was revealed in our survey that eight patients had both factor V and factor VIII i...

To test the hypothesis that factor VIII expressed in the epidermis can correct hemophilia A, we generated transgenic mice in a factor VIII-deficient background that express human factor VIII under control of the involucrin promoter. Mice from 5 transgenic lines had both phenotypic correction and plasma factor VIII activity. In addition to the skin, however, some factor VIII expression was detec...

We prepared a highly purified and relatively heat stable form of factor VIII which contained 25 units per mL (u/mL) activity using PEG-4000 and developed an effective and new manufacturing process. Heat treatment was performed at 80°C for 72 hrs in the presence of different stabilizers. In our studies, we used different organic solvents as preservatives to maintain factor VIII activity, sin...

Factor VIII (antihemophilic factor) has been purified approximately 500.fold from the cryoprecipitate fraction of human plasma. The isolation procedure involves adsorption of contaminants with Al(OH),, column chromatography on tricalcium citrate-cellulose, precipitation with concanavalin A, and an agarose gel filtration step. The linal product is homogeneous when examined by zone electrophoresi...

objective(s): the purpose of the present study was the immunohistochemical evaluation of vegf and vii factors in dog’s teeth pulp revascularized with mta and propolis. materials and methods: 144 mature and immature two rooted dog’s premolar canals were selected.  pulp necrosis and infection were established after 2 weeks and the disinfection of the canals was done with copious naocl irrigation ...

The factor VIII C2 domain is essential for binding to activated platelet surfaces as well as the cofactor activity of factor VIII in blood coagulation. Inhibitory antibodies against the C2 domain commonly develop following factor VIII replacement therapy for hemophilia A patients, or they may spontaneously arise in cases of acquired hemophilia. Porcine factor VIII is an effective therapeutic fo...

Purified human Factor X (apparent mol.wt. 72000), which consists of two polypeptide chains (mol.wt. 55000 and 19000), was activated by both Russell's-viper venom and the purified physiological activators (Factor VII/tissue factor and Factor IXa/Factor VIII). They all convert Factor X to catalytically active Factor Xa (mol.wt. 54000) by cleaving the heavy chain at a site on the N-terminal region...

Background: Factor VIII administration to hemophilia A patients results in an immune response (inhibitor formation) which significantly complicates the therapy. The present study was performed to determine the prevalence of inhibitor development in hemophilia A patients receiving recombinant factor VIII therapy. Materials and Methods: This was an observational descriptive study. Clotting fac...

Coagulation factor Va is a cofactor which combines with the serine protease factor Xa on a phospholipid surface to form the prothrombinase complex. The phospholipid-binding domain of bovine factor Va has been reported to be located on the light chain of the molecule and more precisely on a fragment of Mr = 30,000 which is obtained after digestion of factor Va light chain by factor Xa. This prot...